InSphero grows further with $10 million funding round
18.06.2018
3D cell culture pioneer Insphero has raised new financing from internal and external investors, bringing its total investment to date to $35 million.
 |
 |
The medtech’s drug discovery and testing platforms use ground-breaking, scaffold-free 3D microtissues – phenotypic models of the smallest functional unit of a tissue or organ – driven by cellular self-assembly. With organs grown in vitro in this way, the effects of a drug, or a disease, can be studied realistically without animal testing.
Insphero already counts all top 10 pharmaceutical companies among its customers, and its new “organ on a chip” technology Akura™ Flow takes the possibilities even further, providing insights into how drugs affect the entire human body. The funding announcement also follows closely on a partnership with ALPCO to offer a complete diabetes discovery platform.
The startup was a 2008 Venture Kick winner. InSphero CEO and co-founder Dr. Jan Lichtenberg said: “Venture Kick helped us to turn our idea into an operative business. It’s been a success story that we are very grateful for!”
Insphero already counts all top 10 pharmaceutical companies among its customers, and its new “organ on a chip” technology Akura™ Flow takes the possibilities even further, providing insights into how drugs affect the entire human body. The funding announcement also follows closely on a partnership with ALPCO to offer a complete diabetes discovery platform.
The startup was a 2008 Venture Kick winner. InSphero CEO and co-founder Dr. Jan Lichtenberg said: “Venture Kick helped us to turn our idea into an operative business. It’s been a success story that we are very grateful for!”